1. Home
  2. IMNN vs EDUC Comparison

IMNN vs EDUC Comparison

Compare IMNN & EDUC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMNN
  • EDUC
  • Stock Information
  • Founded
  • IMNN 1982
  • EDUC 1965
  • Country
  • IMNN United States
  • EDUC United States
  • Employees
  • IMNN N/A
  • EDUC N/A
  • Industry
  • IMNN Biotechnology: Pharmaceutical Preparations
  • EDUC Consumer Specialties
  • Sector
  • IMNN Health Care
  • EDUC Consumer Discretionary
  • Exchange
  • IMNN Nasdaq
  • EDUC Nasdaq
  • Market Cap
  • IMNN 12.1M
  • EDUC 11.4M
  • IPO Year
  • IMNN 1985
  • EDUC N/A
  • Fundamental
  • Price
  • IMNN $1.46
  • EDUC $1.35
  • Analyst Decision
  • IMNN Buy
  • EDUC
  • Analyst Count
  • IMNN 2
  • EDUC 0
  • Target Price
  • IMNN $14.00
  • EDUC N/A
  • AVG Volume (30 Days)
  • IMNN 31.5M
  • EDUC 12.9K
  • Earning Date
  • IMNN 05-12-2025
  • EDUC 07-10-2025
  • Dividend Yield
  • IMNN N/A
  • EDUC N/A
  • EPS Growth
  • IMNN N/A
  • EDUC N/A
  • EPS
  • IMNN N/A
  • EDUC N/A
  • Revenue
  • IMNN N/A
  • EDUC $34,191,000.00
  • Revenue This Year
  • IMNN N/A
  • EDUC N/A
  • Revenue Next Year
  • IMNN N/A
  • EDUC N/A
  • P/E Ratio
  • IMNN N/A
  • EDUC N/A
  • Revenue Growth
  • IMNN N/A
  • EDUC N/A
  • 52 Week Low
  • IMNN $0.37
  • EDUC $0.92
  • 52 Week High
  • IMNN $3.65
  • EDUC $2.49
  • Technical
  • Relative Strength Index (RSI)
  • IMNN 52.73
  • EDUC 53.21
  • Support Level
  • IMNN $0.85
  • EDUC $1.31
  • Resistance Level
  • IMNN $3.16
  • EDUC $1.64
  • Average True Range (ATR)
  • IMNN 0.52
  • EDUC 0.14
  • MACD
  • IMNN 0.03
  • EDUC -0.00
  • Stochastic Oscillator
  • IMNN 39.07
  • EDUC 33.14

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

About EDUC Educational Development Corporation

Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.

Share on Social Networks: